OmniAb Inc. Market Cap ($716.17 Million)
Market Cap & Net Worth: OmniAb Inc. (OABI)
OmniAb Inc. market cap. OmniAb Inc. (NASDAQ:OABI) has a market capitalization of $716.17 Million ($716.17 Million) as of November 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10206 globally and #2771 in its home market, demonstrating a 1.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OmniAb Inc.'s stock price $4.91 by its total outstanding shares 145860318 (145.86 Million). Also see OABI cash flow metrics for how efficiently the company converts equity into cash flow.
OmniAb Inc. Market Cap History (2021–2026)
OmniAb Inc. market cap history from 2021 to 2026. Data shows change from $1.46 Billion to $716.17 Million (-12.55% CAGR). Check OmniAb Inc. stock quote for real-time trading data and today's change.
Index Memberships
OmniAb Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.74 Trillion | 0.03% | #288 of 976 |
|
NASDAQ Composite
IXIC
|
$40.13 Trillion | 0.00% | #1059 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.92 Trillion | 0.04% | #169 of 263 |
Weight: OmniAb Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OmniAb Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OmniAb Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore OmniAb Inc. annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
14.46x
OmniAb Inc.'s market cap is 14.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.46 Billion | $34.75 Million | -$27.04 Million | 41.98x | N/A |
| 2022 | $525.10 Million | $59.08 Million | -$22.33 Million | 8.89x | N/A |
| 2023 | $899.96 Million | $34.16 Million | -$50.62 Million | 26.34x | N/A |
| 2024 | $516.35 Million | $26.39 Million | -$62.03 Million | 19.57x | N/A |
| 2025 | $269.84 Million | $18.67 Million | -$64.78 Million | 14.46x | N/A |
Competitor Companies of OABI by Market Capitalization
Companies near OmniAb Inc. in the global market cap rankings as of November 15, 2026. Also see OmniAb Inc. asset portfolio for a full breakdown of the balance sheet.
Key companies related to OmniAb Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #286 globally with a market cap of $93.55 Billion USD.
- Moderna Inc (NASDAQ:MRNA): Ranked #304 globally with a market cap of $90.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $69.66 Billion USD ( AU$98.45 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $538.60 |
| #286 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $93.55 Billion | $955.47 |
| #304 | Moderna Inc | NASDAQ:MRNA | $90.38 Billion | $223.37 |
| #412 | CSL Ltd | AU:CSL | $69.66 Billion | AU$202.92 |
Market Capitalization of OmniAb Inc. (2021–2026)
Market capitalization of OmniAb Inc. from 2021 to today. Between 2021 and today, OmniAb Inc.'s market cap moved from $1.46 Billion to $ 716.17 Million, with a yearly change of -12.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $716.17 Million | +165.41% |
| 2025 | $269.84 Million | -47.74% |
| 2024 | $516.35 Million | -42.63% |
| 2023 | $899.96 Million | +71.39% |
| 2022 | $525.10 Million | -64.00% |
| 2021 | $1.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 15th, 2026 the market cap of OmniAb Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $716.17 Million USD |
| MoneyControl | $716.17 Million USD |
| MarketWatch | $716.17 Million USD |
| marketcap.company | $716.17 Million USD |
| Reuters | $716.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more